TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06490627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period.
Study: NCT06014892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snoo smart bassinet
Description: Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Willow wearable breast pump
Description: Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maven Clinic on-demand perinatal consultation
Description: Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faculty mentor
Description: After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
Study: NCT06175403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
Study: NCT04405115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Assessment
Description: Geriatric Assessment Visit
Study: NCT06290349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-T1
Description: DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-T2
Description: DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA5221-B1
Description: DA5221-B1, orally, daily for background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-B1
Description: DA5221-B1, orally, daily for background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-B1
Description: DA5221-B1, orally, daily for background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA5221-B2
Description: DA5221-B2, orally, daily for background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-B2
Description: DA5221-B2, orally, daily for background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA5221-B2
Description: DA5221-B2, orally, daily for background therapy
Study: NCT05085951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 mm CRE balloon
Description: Endoscopic balloon that is used to dilate pylorus

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: OGD
Description: OGD (No dilatation)
Study: NCT05522179

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutraHeal
Description: Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutraHeal Plus
Description: Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
Study: NCT06156436

Intervention type: DEVICE
Intervention: ResAppDx v.20
Description: Software application used to aid diagnosis of respiratory disorders
Study: NCT05275348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Enhance Fitness
Description: Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Enhance Fitness
Description: Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
Study: NCT05774730

Intervention type: OTHER
Intervention: Emphysema quantitative analysis software based on chest image AI technology
Description: The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.

Intervention type: OTHER
Intervention: artificial analysis of chest image
Description: The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.

Intervention type: PROCEDURE
Intervention: imported Chartis detection system
Description: The participants would undergo imported Chartis detection system.
Study: NCT04278963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YinHu QingWen Decoction
Description: YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YinHu QingWen Decoction(low dose)
Description: This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine treatment
Description: This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
Study: NCT04745039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopatch System
Description: The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
Study: NCT06125769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
Study: NCT04092348

Intervention type: OTHER
Intervention: complete blood count
Description: 1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene.

Intervention type: OTHER
Intervention: complete blood count
Description: 1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene.
Study: NCT04858451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day.
Study: NCT05401084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient diet changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient diet changes.
Study: NCT04188574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-1
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine

Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-1
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-3
Description: Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine

Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-3
Description: Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-10
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine

Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-10
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
Study: NCT04922840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIIT)
Description: 12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
Study: NCT05425615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS
Study: NCT05758519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128
Description: QLS1128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05160155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Serratus anterior plane block will be performed unilaterally, under US guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Block
Description: Intercostal Block will be performed unilaterally, under US guidance.
Study: NCT06072521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
Study: NCT04881825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Glepaglutide will be delivered in a single-use autoinjector.
Study: NCT05119608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/ACT
Description: 10-session ACT-re-enforced CBT intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT/ACT
Description: 10-session ACT-re-enforced CBT intervention.
Study: NCT05338177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunosuppression reduction
Description: participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No immunosuppression reduction
Description: participants do not alter immunosuppresion
Study: NCT06293248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musical application
Description: Rast, Acemasiran, and Huseyni from Classical Turkish Music modes were optionally offered to the patients in the music group, and the patient's preferred music was listened to through headphones for 15-20 minutes before the CAG procedure. Following the interviews, musical genres were arranged as instrumental, without words, at 70 decibels in terms of rhythm and duration, at approximately 60 metronomes per minute, and were played according to the person's preference. Instrumental music was loaded onto the portable MP3 player provided by the researchers.
Study: NCT05171348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: a humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: a humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: a humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: a humanized monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06466304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
Study: NCT05018039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborarive Care Model
Description: Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care).
Study: NCT05376475

Intervention type: DEVICE
Intervention: Infrared video-audio camera
Description: Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA

Intervention type: DEVICE
Intervention: Infrared video-audio camera
Description: Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA

Intervention type: DEVICE
Intervention: Level III home sleep apnea test
Description: NightOwl® by Ectosense, Leuven, Belgium

Intervention type: DEVICE
Intervention: Level III home sleep apnea test
Description: NightOwl® by Ectosense, Leuven, Belgium

Intervention type: DEVICE
Intervention: Maternal-fetal transabdominal electrocardiographic heart rate monitor
Description: The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK

Intervention type: DEVICE
Intervention: Pressure sensing mat
Description: Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
Study: NCT06489587

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
Study: NCT05565716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Person
Description: Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Norms
Description: Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
Study: NCT04898075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Contingency Management (CM) for nicotine abstinence
Description: Participants will be paid increasing amounts of payment for each negative saliva cotinine test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
Study: NCT05177653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GIP receptor antagonist (GIP(3-30)NH2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GLP-1 receptor antagonist (exendin(9-39)NH2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GIP(3-30)NH2 and exendin(9-39)NH2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion
Description: Saline
Study: NCT06410365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Comparison of intravenous and intrathecal route of dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Comparison of intravenous and intrathecal route of dexmedetomidine
Study: NCT05289570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: 500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
Study: NCT05341362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LiDCOrapid
Description: According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
Study: NCT05095870

Intervention type: OTHER
Intervention: No intervention
Description: Pure observational study

Intervention type: OTHER
Intervention: No intervention
Description: Pure observational study